Developing new therapies for neurological diseases is very expensive…
Filed under: Message From the Editor | Tagged: clinical trials, higher drug prices, Institutional Review Board, IRB, neurological diseases, NIH, phase I-III | Leave a Comment »
-
Recent Posts
- DISCOVERIES IN NEUROSCIENCE September 2009
- MESSAGE FROM THE EDITOR: Balancing risk and reward: the question of natalizumab September 2009
- Message from the Editor: Disparities in Care: Guilty Until Proven Innocent
- DISCOVERIES IN NEUROSCIENCE August 2009 Translating omics into drug discovery
- NERVECENTER Lyme Wars Update: New Conn. Law Protects Physicians Treating ‘Chronic Lyme’
Categories
Archives
Calendar
Blogroll
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
